Azenta, Inc. Provides Earnings Guidance for the Third Fiscal Quarter Ended June 30, 2022
July 13, 2022 at 04:05 pm EDT
Share
Azenta, Inc. provided earnings guidance for the third fiscal quarter ended June 30, 2022. For the quarter, the company expects revenue of approximately $133 million, an increase of 3% compared to the third quarter of fiscal 2021. GAAP diluted EPS from continuing operations is expected to be in the range of negative $0.13 to negative $0.08, driven lower than expected primarily due to income taxes.
Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Companyâs segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.
AZENTA, INC. 
